Skip to main content
Clinical Trials/ACTRN12616000464460
ACTRN12616000464460
Terminated
未知

Case Series Study: Treatment of Osteochondral Defects in the Hip Using Microfracture Augmented with CelGro (Trademark) Collagen Matrix

Orthocell Ltd.0 sites7 target enrollmentApril 8, 2016

Overview

Phase
未知
Intervention
Not specified
Conditions
Cartilage defect hip
Sponsor
Orthocell Ltd.
Enrollment
7
Status
Terminated
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 8, 2016
End Date
June 27, 2019
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Male or female between 18\-55 years of age
  • \- Acetabular osteochondral defect (Outerbridge grade III or IV) measuring 2\-8cm2
  • \- Radiologically confirmed Tonnis grade \< 2
  • \- Able to comply with the requirements of the protocol, including post\-treatment rehabilitation
  • \- Able to give informed consent or has legally acceptable representative who can give informed consent in accordance with ICH/GCP

Exclusion Criteria

  • \- Concomitant presence of femoral head chondral lesion (kissing lesion)
  • \- Rheumatoid arthritis
  • \- Dysplasia
  • \- Femoral neck axial deviation
  • \- Coxa profunda
  • \- Protrusio acetabuli
  • \- Active infection or systemic pathology including inflammatory joint disease, HIV, uncontrolled or poorly controlled diabetes, hepatitis or neoplastic disorders
  • \- Known hypersensitivity to the study treatment or its excipients or known relevant medication allergy
  • \- Female participant who is pregnant or lactating
  • \- Known substance abuse

Outcomes

Primary Outcomes

Not specified

Similar Trials